Becton Dickinson (BDX)Director bought ~$350K

~$350K

Approx. value · 1,500 sh @ $233.62

8,015

Holds after · shares reported

Traded

Feb 10, 2025

Filed

Feb 10, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 19, 2024InsiderOfficer sold ~$634K of BDX shares in the open market
2. Jan 7, 2025InsiderOfficer sold ~$185K of BDX shares in the open market
3. Jan 17, 2025InsiderOfficer sold ~$141K of BDX shares in the open market
4. Jan 21, 2025Insider · 2 peopleInsiders: 2 sales (~$309K)
5. Feb 10, 2025 · this disclosureInsiderDirector purchased ~$350K of BDX shares in the open market

What came next

1. Feb 12, 2025InsiderDirector sold ~$160K of BDX shares in the open market
2. Mar 5, 2025CongressDisclosed sale of BDX — reported range $15,001 - $50,000
3. Mar 12, 2025InsiderOfficer sold ~$436K of BDX shares in the open market
4. Mar 18, 2025InsiderOfficer sold ~$106K of BDX shares in the open market
5. Apr 8, 2025CongressDisclosed sale of BDX — reported range $1,001 - $15,000
6. Apr 9, 2025InsiderOfficer sold ~$94K of BDX shares in the open market
7. May 15, 2025CongressDisclosed purchase of BDX — reported range $1,001 - $15,000
8. May 21, 2025FDARecall: REF: 381434 BD Insyte Autoguard Shielded IV Catheter, 20 GA x 1.16 in (1.1 x 30 mm) 60 mL/min, STERILEEO, RxOnly
9. May 21, 2025FDARecall: REF: 381923 BD Insyte Autoguard Winged Shielded IV Catheter, 22 GA x 1.00 in (0.9 x 25 mm) 35 mL/min, STERILEEO, RxOnly
10. May 21, 2025FDARecall: REF: 382544 BD Insyte Autoguard Shielded IV Catheter, 18 GA x 1.16 in (1.3 x 30 mm) 95 mL/min, STERILEEO, RxOnly
11. May 21, 2025FDARecall: REF: 381433, BD Insyte Autoguard Shielded IV Catheter, 20GA x 1.00 in (1.1x25 mm) 65 mL/min, STERILEEO, RxOnly
12. May 21, 2025FDARecall: REF: 381423, BD Insyte Autoguard, Shielded IV Catheter, 22GA X 1.00 IN (0.9 X 25 MM) 35mL/min, STERILEEO, RxONLY
13. May 21, 2025FDARecall: REF: 382944, BD Insyte Autoguard BC Pro Winged Shielded IV Catheter, 18 GA x 1.16 in (1.3 x 30 mm) 95 mL/min, STERILEEO, RxOnly
14. May 21, 2025FDARecall: REF: 381533, BD Insyte Autoguard Winged, Shielded IV Catheter, 20 GA x 1.00 in (1.1 x 25 mm) 65mL/min, STERILEEO,RxOnly
15. May 21, 2025FDARecall: REF: 381811, BD Insyte Autoguard BC Pro Winged Shielded IV Catheter, 18 GA x 1.16 in (1.3 x 30 mm) 95 mL/min, STERILEEO, RxOnly
16. May 21, 2025FDARecall: REF: 382633, BD Insyte Autoguard BC Winged, Shielded IV Catheter with Blood Control Technology, 20GA x 1.00 in (1.1x25 mm) 63 mL/min, STERILEEO, RxOnly
17. Jun 2, 2025InsiderOfficer sold ~$200K of BDX shares in the open market
18. Jun 3, 2025FDAFDA device clearance: BD Nexiva™ Diffusics™ Closed IV Catheter System and BD Nexiva™ Diffusics™ Closed IV Catheter System with BD MaxZero™ Needle-free Connector
19. Jun 3, 2025FDARecall: REF: 666289 , BD FACS, 7-Color Setup Beads, 25 Runs, CE, IVD. Used in flow cytometry for fluorescence compensation.
20. Jun 3, 2025FDARecall: REF: 123400,Bard Urologist's Tray, For the Obstructed Urethra

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Becton Dickinson

For Becton Dickinson, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 28 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BDX page.

Other recent filings by Jeffrey William Henderson, Director

• SEC Form 4 at Halozyme (HALO)Apr 28, 2025
• SEC Form 4 at Halozyme (HALO)Apr 28, 2025
• SEC Form 4 at Halozyme (HALO)Apr 1, 2025
• SEC Form 4 at Halozyme (HALO)Mar 4, 2025
• SEC Form 4 at Halozyme (HALO)Mar 4, 2025

The full history of Jeffrey William Henderson, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Becton Dickinson

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Aug 27, 2026
• SEC Form 13F-HRAug 18, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its BDX page.